hx009
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2019 (NCT04097769)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06708663 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Government of China |
| NCT05189093 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Chinese Academy of Medical Sciences, Waterstone Hanxbio Pty Ltd |
| NCT04886271 | Phase 2 | May 10, 2021 | Chinese Academy of Medical Sciences, Waterstone Hanxbio Pty Ltd |
| NCT05731752 | Phase 1 | Jun 4, 2020 | Government of China |
| NCT04097769 | Phase 1 | Jun 12, 2019 | St. George Private Hospital, Waterstone Hanxbio Pty Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Waterstone Hanxbio Pty Ltd | For profit | 3 | 3 | 2 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Government of China | Government | 2 | 2 | 2 | 2020 |
| St. George Private Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1